Valacyclovir Uses: Cold Sores, Genital Herpes, Shingles, and Chickenpox

What valacyclovir is and what it does

Valacyclovir is an oral prescription antiviral medication used to manage infections caused by herpes viruses. It is not active on its own. Once swallowed, it is rapidly converted in the body into acyclovir, the compound that actually does the work. This design, known as a prodrug, allows the medication to be absorbed more efficiently than acyclovir taken directly, though the antiviral effect ultimately comes from acyclovir itself.

Acyclovir works by interfering with the enzyme herpesviruses use to copy their DNA. Herpes simplex virus and varicella-zoster virus (the virus behind chickenpox and shingles) both need this enzyme to multiply. By blocking it, valacyclovir slows down viral replication, which is why it helps control outbreaks.

What it does not do is remove the virus from the body. Herpesviruses establish a latent, dormant presence in nerve tissue after the initial infection, and no currently available antiviral clears this latent reservoir. Valacyclovir controls active replication while it's being taken; it does not change the underlying fact that the virus remains in the body afterward, and it does not alter a person's long-term recurrence risk once treatment stops. Understanding this distinction, between suppressing an active infection and eliminating the virus, is central to understanding everything else valacyclovir can and cannot do.

FDA-approved uses by infection and age

Valacyclovir's approved uses depend heavily on the specific infection, the patient's age, and their immune status, so it helps to look at them separately rather than as one general “herpes medication.”

In adults with a healthy immune system, valacyclovir is approved for:

• Cold sores (herpes labialis)
• Genital herpes, covering initial outbreaks, recurrent episodes, and long-term suppression to reduce how often recurrences happen
• Shingles (herpes zoster)
• Reducing the risk of transmitting genital herpes to a partner

Genital herpes suppression also has a second approved population: certain adults living with HIV-1 infection, under label-specified conditions.

In children, the approved uses are narrower. Valacyclovir is approved for cold sores in patients 12 years of age and older, and for chickenpox in immunocompetent children between 2 and under 18 years old. Genital herpes and shingles are not approved pediatric uses under this label.

What falls outside this approved scope: efficacy and safety have not been established for other immunocompromised groups beyond the specified HIV-1 population noted above, and uses such as cytomegalovirus prevention are not part of this drug's approved indications, even though they sometimes appear in other contexts. Whether valacyclovir is appropriate for a given infection depends on matching the specific diagnosis, age, and immune status to these boundaries.

Episodic treatment versus suppressive therapy

For recurrent genital herpes, valacyclovir can be used in two distinct ways, and the difference matters for understanding what a prescription is actually meant to accomplish.

Episodic therapy means treatment is started around the time an outbreak begins, typically at the earliest sign of symptoms. The goal is to improve or shorten that particular episode. It's a short course tied to a specific flare-up, not an ongoing daily medication.

Suppressive therapy is different. It involves taking valacyclovir on a regular, ongoing basis, whether or not symptoms are present, with the goal of reducing how often recurrences happen over time. This approach is an established option for people with recurrent genital herpes, including specified adults with HIV-1 infection, though whether to use episodic or suppressive therapy, and for how long, is an individualized decision made with a clinician based on how often outbreaks occur and how much they affect someone's life.

The scale of benefit from suppression has been studied at the population level: among patients with frequent recurrences, CDC guidance reports a 70 to 80 percent reduction in outbreak frequency with suppressive therapy. That figure describes what has been observed across groups of patients, not a guaranteed result for any one individual, and it does not mean recurrences stop entirely. The regimens themselves, and how they relate to timing, are covered separately in the sections ahead, along with what suppressive therapy means for reducing transmission risk to a partner.

Can valacyclovir prevent genital herpes transmission?

Daily suppressive valacyclovir can lower the risk of transmitting genital herpes to a sexual partner, but it does not eliminate that risk. This is one of the more specific and frequently misunderstood aspects of the drug's approved use.

The supporting evidence comes from a particular studied setting: heterosexual couples where one partner has symptomatic genital HSV-2 infection and the other partner does not. Taking valacyclovir consistently was shown to reduce transmission of the virus to the uninfected partner. That's a meaningful finding, but it's also a bounded one. The same level of evidence has not been established for genital HSV-1, for asymptomatic HSV-2 infection, or for every type of relationship or partnership pairing. Applying this transmission-reduction benefit beyond the setting where it was studied isn't supported by the available evidence.

Because the reduction in risk is partial rather than complete, CDC guidance frames suppressive therapy as one part of a broader risk-reduction approach rather than a stand-alone solution. Consistent condom use and avoiding sexual activity during active recurrences are recommended alongside suppressive treatment, not as optional extras. Valacyclovir can meaningfully lower the odds of transmission in the setting where it's been studied, but it works as a complement to other precautions, not a replacement for them.

When and how valacyclovir is taken

There is no single valacyclovir regimen. How it's dosed and for how long depends on which infection is being treated, whether it's an initial episode or a recurrence, the patient's age, their immune status, and how well their kidneys are functioning. This is why one person's prescription can look completely different from another's, even for what seems like a similar condition.

To illustrate the range rather than to serve as a dosing guide, labeled regimens include examples as short as a single day of treatment for cold sores, a few days for a recurrent genital herpes episode, about a week for shingles, and ongoing daily dosing for genital herpes suppression. Kidney function can also require the dose to be adjusted downward. Because of this variability, a regimen that worked for a friend or family member's infection isn't a reliable guide for someone else's prescription, even if the diagnosis sounds the same.

Tablets can be taken without regard to meals, which offers some flexibility in timing. For outbreak-related treatment, starting the medication promptly, at the early symptom or rash stage specified for that condition, is part of how these regimens are designed to work. The practical details of a specific dose and duration should come from the prescribing clinician rather than a general information source.

What valacyclovir can and cannot accomplish

Bringing together how valacyclovir works with its approved uses, it's worth being clear about the realistic scope of what this medication offers.

Valacyclovir can control active viral replication while it's being taken. Used episodically, it can help manage an outbreak. Used suppressively for recurrent genital herpes, it can meaningfully reduce how often recurrences occur, based on population-level evidence, and in the specific studied setting of symptomatic genital HSV-2 in heterosexual couples, it can lower the risk of transmission to a partner.

What it cannot do is eliminate the latent virus that persists in the body after infection, whether that's herpes simplex virus or varicella-zoster virus. It also cannot guarantee that a particular person will never have another outbreak, or that transmission to a partner will never happen. The reduction in recurrences and in transmission risk is real but partial, and it applies specifically within the populations and settings where it has been studied.

Resisting the temptation to predict exactly how fast symptoms will resolve or how much any one person will benefit. Response to treatment varies, and the available evidence describes group-level outcomes rather than individual guarantees. Thinking of valacyclovir as a tool for managing an ongoing viral infection, rather than as a cure, sets more accurate expectations for what a prescription is meant to achieve.

Who needs additional caution or individualized dosing

Certain patient factors change how valacyclovir should be used, and these are situations calling for clinician oversight rather than self-adjustment of a dose.

Kidney function is one of the most significant. Acute renal failure has been reported with valacyclovir, particularly in older adults, people with underlying kidney disease who receive a dose too high for their reduced kidney function, those taking other medicines that can affect the kidneys, and patients who aren't adequately hydrated. This is why the label calls for caution in older adults, dose reduction when kidney function is impaired, and attention to hydration, rather than treating kidney disease itself as a reason to avoid the drug altogether. Reduced kidney function calls for a different, individualized dose, not automatic exclusion from treatment.

Immune status matters as well. Outside of genital herpes suppression in specified adults with HIV-1 infection, the evidence supporting valacyclovir's use in other immunocompromised populations is limited under the current label, which is part of why treatment decisions in that setting need individualized clinical judgment.

Pregnancy and breastfeeding also call for individualized assessment rather than a blanket answer. Decades of available data have not identified a drug-associated risk of major birth defects, and acyclovir does pass into breast milk after valacyclovir is taken. Neither of these facts makes the medication automatically appropriate or automatically inadvisable in a given situation; that determination depends on weighing clinical need against exposure considerations for a specific patient and infant.

Side effects, serious warnings, and contraindications

Most people who take valacyclovir experience, at most, mild and manageable side effects. Across studies of its approved adult uses, the most commonly reported effects occurring more often than with placebo are headache, nausea, and abdominal pain.

Separate from these common effects, the label includes more serious warnings that call for prompt clinical attention rather than routine monitoring. These include acute kidney failure, central nervous system effects, and, in specific severely immunocompromised populations exposed to very high doses, a serious blood disorder involving thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Severe skin reactions are also a recognized concern; the label specifically directs that valacyclovir be stopped right away if a painful rash involving the mucous membranes (such as the mouth, eyes, or genitals) develops, or if a rash becomes progressively more severe.

The medication's actual contraindication is narrower than some of these warnings might suggest: valacyclovir should not be used by anyone who has had a clinically significant hypersensitivity reaction to valacyclovir, to acyclovir, or to any component of the tablet formulation. Kidney disease, by contrast, is a reason for dose adjustment and closer monitoring, not an outright bar to treatment.

Anyone experiencing signs of a severe reaction, a spreading rash with mucosal involvement, confusion or other neurological changes, or a marked drop in urination should contact a clinician promptly rather than waiting to see if symptoms resolve on their own.